Dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.
Project details
- Project no.
- A19-88
- Commission
- Commission awarded on 15.10.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed